Nykredit A/S’s Spyre Therapeutics SYRE Stock Holding History

Nykredit A/S’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	+1,953	New	+$143K	﹤0.01%	1093

Other funds holding SYRE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nykredit A/S's SYRE Position: Q2 2026 in Review

Nykredit A/S opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 1,953 shares worth $173K. The stake represents ﹤0.01% of the portfolio and ranks #1093 among its holdings.

150 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Nykredit A/S held 1,953 shares of Spyre Therapeutics worth $173K as of Q2 2026.
Spyre Therapeutics was a new Nykredit A/S position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1093 holding.
150 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.